Wednesday, February 27, 2019
Financial News Conference Full Year 2018 results
Location: Leverkusen, Baykomm (Bayer‘s Communication Center)
Bayer confirms 2019 Group outlook and 2022 targets
- Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros
- EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros
- Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings
- Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline
- Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start
- Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits
- Net income at 1.695 billion euros, impacted by one-time effects
- Core earnings per share at 5.94 euros, above expectations
- Net financial debt at 35.679 billion euros, significantly better than expected
- Bayer confirms 2019 Group outlook and 2022 targets
Links
Recording of the Conference
Audio: MP3 for download (50.37 MB, 107:24 min.) (dubbed into English)
Speaker
Statement in written form and presentation slides
Recording (dubbed into English):
Video: Webcast of the speech with presentation slides (part 1)
Video: Webcast of the speech with presentation slides (part 2)
Audio: MP3 of the speech for download (part 1; MP3, 6.61 MB, 14:04 min.)
Audio: MP3 of the speech for download (part 2; MP3, 6.95 MB, 14:47 min.)
Recording (partly dubbed into English):
Video: Webcast of the discussion with presentation slides
Audio: MP3 of the discussion for download (MP3, 29.06 MB, 61:57 min.)